[PDF][PDF] Little evidence for usefulness of biomarkers for predicting successful dose reduction or discontinuation of a biologic agent in rheumatoid arthritis: a systematic …

L Tweehuysen, CH van den Ende… - Arthritis & …, 2017 - Wiley Online Library
Objective To systematically review studies addressing prediction of successful dose
reduction or discontinuation of a biologic agent in rheumatoid arthritis (RA). Methods …

[HTML][HTML] bDMARD dose reduction in rheumatoid arthritis: a narrative review with systematic literature search

LM Verhoef, L Tweehuysen, ME Hulscher… - Rheumatology and …, 2017 - Springer
Introduction Although bDMARDs are effective in the treatment of RA, they are associated
with dose-dependent side effects, patient burden, and high costs. Recently, many studies …

Subjective complaints as the main reason for biosimilar discontinuation after open‐label transition from reference infliximab to biosimilar infliximab

L Tweehuysen, BJF van den Bemt… - Arthritis & …, 2018 - Wiley Online Library
Objective To evaluate drug survival, effectiveness, pharmacokinetics, immunogenicity, and
safety in daily practice after transitioning treatment from original reference infliximab …

Open‐label, non‐mandatory transitioning from originator etanercept to biosimilar SB 4: six‐month results from a controlled cohort study

L Tweehuysen, VJB Huiskes… - Arthritis & …, 2018 - Wiley Online Library
Objective To evaluate the effects of non‐mandatory transitioning from the originator biologic
drug etanercept (ETN) to its biosimilar, SB 4, on drug survival and effectiveness in a …

[HTML][HTML] The discriminative capacity of soluble Toll-like receptor (sTLR) 2 and sTLR4 in inflammatory diseases

J Ten Oever, M Kox, FL van de Veerdonk… - BMC immunology, 2014 - Springer
Background The extracellular domains of cytokine receptors are released during
inflammation, but little is known about the shedding of Toll-like receptors (TLR) and whether …

Flares in rheumatoid arthritis patients with low disease activity: predictability and association with worse clinical outcomes

K Bechman, L Tweehuysen, T Garrood… - The Journal of …, 2018 - jrheum.org
Objective. To investigate predictors of flare in rheumatoid arthritis (RA) patients with low
disease activity (LDA) and to evaluate the effect of flare on 12-month clinical outcomes …

Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis

L Tweehuysen, N den Broeder, N Van Herwaarden… - RMD open, 2018 - rmdopen.bmj.com
Objectives Calprotectin (S100A8/A9) has been correlated with disease activity in rheumatoid
arthritis (RA). The aim of this study was to investigate the predictive value of serum …

Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the …

E Ulijn, N den Broeder, M Wientjes… - Annals of the …, 2020 - ard.bmj.com
Background After adalimumab treatment failure, tumour necrosis factor inhibition (TNFi) and
non-TNFi biological disease-modifying anti-rheumatic drugs (bDMARDs) are equally viable …

[HTML][HTML] Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients

MSMA Damen, K Schraa, L Tweehuysen… - Scientific Reports, 2018 - nature.com
About 60% of RA patients don't achieve good response with biological disease-modifying
anti-rheumatic drugs bDMARD treatment (including TNF inhibitors, TNFi's). Previously, a link …

[PDF][PDF] Predictive value of ex-vivo drug-inhibited cytokine production for clinical response to biologic DMARD therapy in rheumatoid arthritis

L Tweehuysen, AA den Broeder, K Schraa… - Clin Exp …, 2019 - clinexprheumatol.org
Predictive value of ex-vivo drug-inhibited cytokine production for clinical response to
biologic DMARD therapy in rheumatoid art Page 1 Clinical and Experimental …